Xenon Pharmaceuticals Reports FY2025 Results, $130M Additional ATM Sales, and Imminent Phase 3 Epilepsy Data

summarizeSummary

Xenon Pharmaceuticals reported increased net losses and R&D expenses for FY2025, but bolstered its liquidity with an additional $130.0 million from its ATM program in early 2026, ahead of crucial Phase 3 epilepsy data expected in March.

check_boxKey Events

• Full-Year 2025 Financial Results

  The company reported a net loss of $345.9 million for the year ended December 31, 2025, an increase from $234.3 million in 2024. Research and development expenses rose to $300.9 million, up from $210.4 million in 2024, reflecting increased clinical development activities. General and administrative expenses also increased to $79.6 million from $68.9 million.

• Significant Capital Raise via ATM Program

  Under its refreshed At-The-Market (ATM) equity offering program, Xenon Pharmaceuticals sold an additional 3,134,119 common shares for net proceeds of $130.0 million between January 1, 2026, and February 23, 2026. This follows $124.2 million raised through the ATM program as of December 31, 2025, bringing total ATM sales under the refreshed program to $254.2 million, with $95.8 million remaining capacity.

• Cash Position and Runway

  As of December 31, 2025, the company held $586.0 million in cash, cash equivalents, and marketable securities. Management anticipates this capital, combined with recent ATM proceeds, will fund operating expenses and capital expenditure requirements for at least the next 12 months.

• Imminent Phase 3 Epilepsy Data Readout

  Topline data from the Phase 3 X-TOLE2 clinical study of azetukalner in focal onset seizures (FOS) is on track for the first half of March 2026. Other Phase 3 studies for azetukalner in FOS (X-TOLE3), primary generalized tonic-clonic seizures (X-ACKT), major depressive disorder (X-NOVA2, X-NOVA3), and bipolar depression (X-CEED) are ongoing.

auto_awesomeAnalysis

Xenon Pharmaceuticals' annual report provides comprehensive financial results for fiscal year 2025, highlighting a significant increase in net loss and R&D expenses as the company advances its clinical pipeline. Critically, the filing discloses an additional $130.0 million raised through its At-The-Market (ATM) program in early 2026, extending its cash runway. The most impactful news is the confirmation of imminent topline data from the Phase 3 X-TOLE2 study for azetukalner in focal onset seizures, expected in the first half of March 2026, which represents a major near-term catalyst for the company.